Esmo 2020 – J&J goes for broke with lung cancer bispecific
The company’s EGFR and cMet targeted bispecific has generated early but encouraging signals in lung cancer – however, J&J faces stiff competition.
Esmo 2020 – some backing for Beigene’s unusual combo approach
The company is one of very few to have studied combining PD-1 and PD-L1 blockade, an approach still in need of scientific validation.
Esmo 2020 puts Opdivo and Cabometyx back in the game
Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co’s Keytruda plus Inlyta in first-line renal cancer.
Esmo 2020 preview – a kidney cancer showdown gets star billing
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Big pharma spinouts grow up
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
Bristol bets on cytokines again
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
